Condition
Vogt Koyanagi Harada Disease
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 3 (1)
Trial Status
Withdrawn1
Recruiting1
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03399175Not ApplicableRecruitingPrimary
Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease
NCT00407121Phase 3WithdrawnPrimary
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
NCT05496530Not ApplicableUnknown
Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)
NCT05031143Phase 2CompletedPrimary
Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment
Showing all 4 trials